The safety of RhIG in the prevention of haemolytic disease of the newborn

Journal of Obstetrics and Gynaecology

Volumn 27, Issue 6, 2007, Pages 545-557

  Hirose, T G ^a   Mays, D A ^a  

^a GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Diagnosis; Haemolytic disease of newborn; Management; Prevention of HND; Rhesus incompatibility; Safety concerns

Indexed keywords

EXCIPIENT; HYPERRHO; POLYCLONAL ANTIBODY; RHESUS D ANTIBODY; RHOPHYLAC; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ALLOIMMUNIZATION; ANEMIA; BLOOD GROUP ABO SYSTEM; BLOOD GROUP RHESUS SYSTEM; BLOOD TRANSFUSION; CHILL; CHROMOSOME 1; COST EFFECTIVENESS ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EXCHANGE BLOOD TRANSFUSION; FETOMATERNAL TRANSFUSION; FLUSHING; GENE FREQUENCY; GENETIC POLYMORPHISM; GESTATIONAL AGE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERSENSITIVITY REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INTRAVASCULAR HEMOLYSIS; MYALGIA; NAUSEA; NEWBORN HEMOLYTIC DISEASE; PATHOPHYSIOLOGY; PERINATAL MORTALITY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRENATAL PERIOD; PRIMIGRAVIDA; PRIORITY JOURNAL; REVIEW; RHESUS INCOMPATIBILITY; SIDE EFFECT; TREATMENT INDICATION; VIRAL CONTAMINATION; VIRUS TRANSMISSION; VOMITING;

ERYTHROBLASTOSIS, FETAL; HUMANS; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN; TREATMENT OUTCOME;

EID: 34848887437     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443610701469941     Document Type: Review

References (79)

1. ACOG, ed. 1999. Prevention of Rh-D alloimmunization. Washington, DC: American College of Obstetricians and Gynecologists.
2. Avent ND, Reid ME. 2000. The Rh blood group system: a review. Blood 95:375-387.
3. Bichler J, Spycher MO, Amstutz HP, Andresen I, Gaede K, Miescher S. 2004. Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. Transfusion Medicine 14:165-171.
4. Boschetti N, Stucki M, Spath PJ, Kempf C. 2005. Virus safety of intravenous immunoglobulin: future challenges. Clinical Reviews in Allergy & Immunology 29:333-344.
5. Bowman J. 1997. The management of hemolytic disease in the fetus and newborn. Seminars in Perinatology 21:39-44.
6. Bowman J. 2003. Thirty-five years of Rh prophylaxis. Transfusion 43:1661-1666.
7. Bowman JM. 1982. The advantages of intravenous Rh-immune globulin. Clinical Obstetrics and Gynecology 25:341-347.
8. Bowman JM. 1985. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? American Journal of Obstetrics and Gynecology 151:289-294.
9. Bowman JM, Chown B, Lewis M, Pollock JM. 1978. Rh isoimmunisation during pregnancy: antenatal prophylaxis. Canadian Medical Association Journal 118:623-627.
10. Bowman JM, Friesen AD, Pollock JM, Taylor WE. 1980. WinRho: Rh immune globulin prepared by ion exchange for intravenous use. Canadian Medical Association Journal 123:1121-1127.
11. Bowman JM, Pollock JM. 1985. Transplacental fetal hemorrhage after amniocentesis. Obstetrics and Gynecology 66:749-754.
12. Bowman JM, Pollock JM, Penston LE. 1986. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sanguinis 51:117-121.
13. Bowman JM, Pollock JM. 1965. Amniotic fluid spectrophotometry and early delivery in the management of erythroblastosis fetalis. Pediatrics 35:815-835.
14. Brantley TA. 2002. Diagnosing hemolytic disease of the newborn. Clinical Laboratory Science 15:140-143.
15. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. 1994. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sanguinis 67:132-138.
16. Cairns JA. 1998. Economics of antenatal prophylaxis. British Journal of Obstetrics and Gynaecology 105:S19-S22.
17. Carritt B, Kemp TJ, Poulter M. 1997. Evolution of the human RH (rhesus) blood group genes: a 50 year old prediction (partially) fulfilled. Human Molecular Genetics 6:843-850.
18. Cash K, Brown T, Strupp A, Uehlinger J. 1999. Anti-G in a pregnant patient. Transfusion 39:531-533.
19. Centers for Disease Control (CDC). 1987. Lack of transmission of human immunodeficiency virus through Rho(D) immune globulin (Human). Morbidity and Mortality Weekly Report 258:3225.
20. Chavez GF, Mulinare J, Edmonds LD. 1991. Epidemiology of Rh haemolytic disease of the newborn in the United States. Journal of the American Medical Association 265:3270-3274.
21. Chown B. 1954. Anaemias from bleeding of the fetus into the mother's circulation. Lancet 266:1213-1215.
22. Colin Y, Cherif-Zahar B, Le Van KC, Raynal V, Van H, V et al. 1991. Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis. Blood 78:2747-2752.
23. Crowther C, Middleton P. 2000. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database System Review:CD000021.
24. Diamond LK. 1932. Erythroblastosis fetalis and its association with universal edema of the fetus, icterus gravis neonatorum, and anaemia of the newborn. Journal of Pediatrics 1:269-309.
25. Eder AF, Manno C. 2003. Alloimmune haemolytic disease of the fetus and newborn. In: Greer JP, Foerster J, Lukens JN, editors. Wintrobe's clinical hematology. 11th ed. Philadelphia: Lippincott Williams and Wilkins. pp 1183-1200.
26. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A et al. 2000. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sanguinis 78:86-95.
27. Freda VJ, Gorman JG, Pollack W, Bowe E. 1975. Prevention of Rh haemolytic disease - ten years' clinical experience with Rh immune globulin. New England Journal of Medicine 292:1014-1016.
28. Fung K, Eason E. 2003. Prevention of Rh alloimmunisation. Journal of Obstetrics and Gynaecology of Canada 133:1-9.
29. Garratty G. 2005. Do we need to be more concerned about weak D antigens? Transfusion 45:1547-1551.
30. Garratty G, Glynn SA, McEntire R. 2004. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 44:703-706.
31. Goldman JA, Eckerling B. 1972. Prevention of Rh immunisation after abortion with Anti-Rh (D)-immunoglobulin. Obstetrics and Gynecology 40:366-370.
32. Gorman JG, Freda VJ. 1972. Rh immune globulin is indicated for Rh-negative mothers undergoing sterilisation. American Journal of Obstetrics and Gynecology 112:868-869.
33. Grabenstein JD. 2006. Immunofacts: vaccines and immunologic drugs. St Louis: Wolters Kluwer Health. pp 444-459.
34. Harkness UF, Spinnato JA. 2004. Prevention and management of RhD isoimmunisation. Clinics in Perinatology 31:721-742, vi.
35. Hartwell EA. 1998. Use of Rh immune globulin: ASCP practice parameter. American Society of Clinical Pathologists. American Journal of Clinical Pathology 110:281-292.
36. Hensleigh PA. 1983. Reduction of Rh (D) sensitisation: a cost-effective analysis. Obstetrics and Gynecology 61:537-538.
37. Hill LM, Platt LD, Kellogg B. 1980. Rh sensitisation after genetic amniocentesis. Obstetrics and Gynecology 56:459-461.
38. Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M. 1998. Safety profile of WinRho anti-D. Seminars in Hematology 35:S9-S13.
39. Hoppe HH, Mester T, Hennig W, Krebs HJ. 1973. Prevention of Rh-immunisation. Modified production of IgG anti-Rh for intravenous application by ion exchange chromatography (IEC). Vox Sanguinis 25:308-316.
40. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. 1992. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79:826-831.
41. Horowitz B, Wiebe ME, Lippin A, Vandersande J, Stryker MH. 1985. Inactivation of viruses in labile blood derivatives. II. Physical methods. Transfusion 25:523-527.
42. Hughes-Jones NC, Ivona M, Ellis J, Walker W. 1971. Anti-D concentration in mother and child in haemolytic disease of the newborn. Vox Sanguinis 21:135-140.
43. HyperRho. 2005. Package insert. Research Triangle Park: Talecris Biotherapeutics.
44. Kempf C, Stucki M, Boschetti N. 2006. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 35:35-42.
45. Lawlor E, Power J, Garson J, Yap P, Davidson F, Columb G et al. 1999. Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation. Vox Sanguinis 76:138-143.
46. Lee D, Reminton KM, Petteway SR, Jr. 2000. Production of intravenous immunoglobulin and other plasma derived products: focus on safety. Journal of Intravenous Nursing 23:S8-S13.
47. Levine P. 1941. Isoimmunisation in pregnancy: its possible bearing on the etiology of erythroblastosis fetalis. Journal of the American Medical Association 116:825-827.
48. Litwak O, Taswell HF, Banner EA, Keith L. 1970. Fetal erythrocytes in maternal circulation after spontaneous abortion. Journal of the American Medical Association 214:531-534.
49. Meisel H, Reip A, Faltus B, Lu M, Porst H, Wiese M et al. 1995. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 345:1209-1211.
50. Miller JL, Petteway SR, Jr., Lee DC. 2001. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasmaderived therapeutic proteins. Journal of Allergy and Clinical Immunology 108:S91-S94.
51. Neal JL. 2001. RhD isoimmunisation and current management modalities. Journal of Obstetric, Gynecologic, and Neonatal Nursing 30:589-606.
52. Nobel Prize [Internet]. 2006. The Nobel Prize in Physiology or Medicine, 1930. Available at: http://nobelprize org/nobel_prizes/medicine/laureates/1930 (Accessed October 2006).
53. Piet MP, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. 1990. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 30:591-598.
54. Pollack W, Gorman JG, Freda VJ, Ascari WQ, Allen AE, Baker WJ. 1968. Results of clinical trials of RhoGAM in women. Transfusion 8:151-153.
55. Queenan JT, Kubarych SF, Shah S, Holland B. 1971. Role of induced abortion in rhesus immunisation. Lancet 1:815-817.
56. Reid ME, Yazdanbakhsh K. 1998. Molecular insights into blood groups and implications for blood transfusion. Current Opinion in Hematology 5:93-102.
57. Remington. 2006. Remington: the science and practice of pharmacy. 21st ed. Baltimore: Lippincott Williams and Wilkins.
58. RhoGam. 2005. Package insert. Rarian, NJ: Ortho-Clinical Diagnostics.
59. Rhophylac. 2005. Package insert. Berne, Switzerland: SLB Behring AG.
60. Rose PG, Strohm PL, Zuspan FP. 1985. Fetomaternal hemorrhage following trauma. American Journal of Obstetrics and Gynecology 153:844-847.
61. Samson D, Mollison PL. 1975. Effect on primary Rh immunisation of delayed administration of anti-Rh. Immunology 28:349-357.
62. Schleis TG. 2005. The process: New methods of purification and viral safety. Pharmacotherapy 25:73S-77S.
63. Siegel J. 2005. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy 25:78S-84S.
64. Simister NE. 2003. Placental transport of immunoglobulin G. Vaccine 21:3365-3369.
65. Smith DB, Lawlor E, Power J, O'Riordan J, McAllister J, Lycett C et al. 1999. A second outbreak of hepatitis C virus infection from anti-D immunoglobulin in Ireland. Vox Sanguinis 76:175-180.
66. Tabor E. 1999. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168.
67. Tateishi J, Kitamoto T, Mohri S, Satoh S, Sato T, Shepherd A et al. 2001. Scrapie removal using Planova virus removal filters. Biologicals 29:17-25.
68. Thornton JG, Page C, Foote G, Arthur GR, Tovey LA, Scott JS. 1989. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. British Medical Journal 298:1671-1673.
69. Torrance GW, Zipursky A. 1984. Cost-effectiveness of antepartum prevention of Rh immunisation. Clinics in Perinatology 11:267-281.
70. Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC et al. 2003. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sanguinis 84:176-187.
71. Urbaniak SJ. 1998. The scientific basis of antenatal prophylaxis. British Journal of Obstetrics and Gynaecology 105:11-18.
72. Van Holten RW, Autenrieth S, Boose JA, Hsieh WT, Dolan S. 2002. Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter. Transfusion 42:999-1004.
73. Von Stein GA, Munsick RA, Stiver K, Ryder K. 1992. Fetomaternal hemorrhage in threatened abortion. Obstetrics and Gynecology 79:383-386.
74. Waldron P, de Alarcon P. 1999. ABO haemolytic disease of the newborn: a unique constellation of findings in siblings and review of protective mechanisms in the fetalmaternal system. American Journal of Perinatology 16:391-398.
75. Watanabe KK, Busch MP, Schreiber GB, Zuck TF. 2000. Evaluation of the safety of Rh immunoglobulin by monitoring viral markers among Rh-negative female blood donors. Vox Sanguinis 78:1-6.
76. Wells MA, Wittek AE, Epstein JS, Marcus-Sekura C, Daniel S, Tankersley DL et al. 1986. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 26:210-213.
77. WinRho SDF. 2006. Package insert. Winnepeg, Manitoba: Cangene Corporation/Baxter Healthcare Corporation.
78. Yei S, Yu MW, Tankersley DL. 1992. Partitioning of hepatitis C virus during Cohn - Oncley fractionation of plasma. Transfusion 32:824-828.
79. Zuck TF, Preston MS, Tankersley DL, Wells MA, Wittek AE, Epstein JE et al. 1986. More on partitioning and inactivation of AIDS virus in immune globulin preparations. New England Journal of Medicine 314:1454-1455.